Atopic dermatitis

ANAPTYSBIO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AnaptysBio, Inc. and Encourages Investors to Contact the Firm

Thursday, March 26, 2020 - 10:39pm

Investors have until May 26, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 26, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • During the Class Period, the Companys lead asset was etokimab (formerly ANB020), a drug intended for the treatment of various inflammatory diseases.
  • On October 10, 2017the first day of the Class Periodthe Company reported data from an interim analysis of its Phase 2a clinical trial of etokimab in atopic dermatitis.
  • As a result of Defendants' misrepresentations, shares of AnaptysBio common stock traded at artificially inflated prices throughout the Class Period.

Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in Dogs

Tuesday, March 24, 2020 - 12:31pm

The study was a randomized, blinded, placebo-controlled pilot effectiveness study that enrolled 26 client-owned dogs diagnosed with atopic dermatitis to assess the efficacy, safety, and pharmacokinetic profile of KIND-025.

Key Points: 
  • The study was a randomized, blinded, placebo-controlled pilot effectiveness study that enrolled 26 client-owned dogs diagnosed with atopic dermatitis to assess the efficacy, safety, and pharmacokinetic profile of KIND-025.
  • Treatment success for individual dogs at each visit was defined as a 50% or higher reduction from baseline in CADESI-4 or PVAS scores.
  • Positive efficacy signals were also detected with other endpoints including 20mm or higher reduction from baseline in PVAS score.
  • "These positive results mark KindredBio's eighth positive pilot study in a row, half of which relate to canine dermatitis.

Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis

Tuesday, March 24, 2020 - 12:00pm

The global AD treatment market is set to witness healthy growth, with forecasts ranging up to USD $18.3 billion by 2027.

Key Points: 
  • The global AD treatment market is set to witness healthy growth, with forecasts ranging up to USD $18.3 billion by 2027.
  • There is still a significant unmet need in the treatment of atopic dermatitis, especially in pediatric atopic dermatitis, where AD effects 15% to 20% of children.
  • Derm-Biome CSO Dr. Poul Sorensen: Inflammation is a major contributor to physical health problems and chronic diseases such as atopic dermatitis.
  • The results of a Skin Tolerability and Pharmacokinetics Study in swine showed that the compound was well tolerated.

U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis

Tuesday, March 24, 2020 - 10:45am

"The approval of a steroid-free treatment option for this age group offers potential relief for these very young patients."

Key Points: 
  • "The approval of a steroid-free treatment option for this age group offers potential relief for these very young patients."
  • EUCRISA may cause side effects including allergic reactions at or near the application site.
  • EUCRISA is a prescription ointment used on the skin (topical) to treat mild-to-moderate eczema (atopic dermatitis) in adults and pediatric patients 3 months of age and older.
  • 2Pfizer Inc. Pfizer Receives FDA Approval for EUCRISA (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema).

 Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch

Wednesday, March 18, 2020 - 8:15pm

Dupilumab, the active control on these primary endpoints, demonstrated superiority to placebo at Week 12 and Week 16.

Key Points: 
  • Dupilumab, the active control on these primary endpoints, demonstrated superiority to placebo at Week 12 and Week 16.
  • Safety results showed that a larger percentage of patients receiving abrocitinib 200mg experienced adverse events (61.9%) than in other treatment arms.
  • The percentages of patients experiencing adverse events were similar for placebo (53.4%), abrocitinib 100mg (50.8%), and dupilumab (50%).
  • The study was the third trial in the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program for abrocitinib.

US Dermatologists Anticipate the Future of Atopic Dermatitis to Mirror that of the Over-Crowded Psoriasis Market

Tuesday, March 17, 2020 - 7:36pm

A noteworthy example of a company differentiating themselves from the pack is AbbVie, particularly with the launch of their third-in-class IL-23 inhibitor, Skyrizi, in psoriasis.

Key Points: 
  • A noteworthy example of a company differentiating themselves from the pack is AbbVie, particularly with the launch of their third-in-class IL-23 inhibitor, Skyrizi, in psoriasis.
  • Impressively, nearly two-thirds of the 101 US dermatologists surveyed selected Skyrizi as their most preferred IL-23 inhibitor if limited to just one for the treatment of psoriasis, despite Tremfya's almost three-year tenure on the market.
  • According to the Q1 2020 report included in Spherix's RealTime Dynamix: Atopic Dermatitis (US) service, 85% of surveyed dermatologists foresee the AD market emulating that of the crowded psoriasis market.
  • A parallel service, RealTime Dynamix: Atopic Dermatitis (US) , tracks the evolution of the US atopic dermatitis market on a quarterly basis.

Asana BioSciences Announces Topical Sodium Channel Blocker ASN008 Achieves Positive Results for the Treatment of Pruritus in Atopic Dermatitis; and Provides Update on JAK/SYK Inhibitor Gusacitinib in Phase 2 Studies for Chronic Hand Eczema and AD

Tuesday, March 10, 2020 - 11:00am

Asana BioSciences announced today positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis (NCT03798561) for its topical sodium channel blocker, ASN008.

Key Points: 
  • Asana BioSciences announced today positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis (NCT03798561) for its topical sodium channel blocker, ASN008.
  • ASN008 demonstrated low systemic exposure, and safety results show that it was well tolerated with only mild adverse events.
  • We are excited by these clinical data which provide proof-of-concept for ASN008 in the treatment of pruritus associated with atopic dermatitis.
  • Asana is also developing an oral Janus kinase (JAK) and Spleen tyrosine kinase (SYK) inhibitor, gusacitinib, for immunology/dermatology indications such as chronic hand eczema and atopic dermatitis.

Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis

Tuesday, February 11, 2020 - 11:24pm

The safety profile in BREEZE-AD5 was consistent with the known safety findings of baricitinib in AD.

Key Points: 
  • The safety profile in BREEZE-AD5 was consistent with the known safety findings of baricitinib in AD.
  • The full results from the BREEZE-AD5 study will be disclosed at future scientific venues and in peer-reviewed journals.
  • "These positive top-line results show that baricitinib could be an effective treatment option for patients living with moderate- to severe AD whose needs have remained unmet, says Dr. Gooderham, Dermatologist and study investigator.
  • BREEZE-AD5, a multicenter, double-blind, randomized, placebo-controlled, Phase 3 study in adult patients with moderate- to severe atopic dermatitis (AD).

Global Atopic Dermatitis Drugs Market, 2019-2027: Drivers, Restraints & Opportunities During this Period - ResearchAndMarkets.com

Monday, February 10, 2020 - 10:40am

It presents a wealth of information on key market dynamics, including the drivers, market trends, and challenges, as well as the structure of the atopic dermatitis drugs market.

Key Points: 
  • It presents a wealth of information on key market dynamics, including the drivers, market trends, and challenges, as well as the structure of the atopic dermatitis drugs market.
  • The study offers valuable information about the atopic dermatitis drugs market, to illustrate how the market is expected to expand during the forecast period of 2019-2027.
  • This data can help readers interpret the quantitative growth aspects of the atopic dermatitis drugs market for the forecast period.
  • Which are the leading companies in the global atopic dermatitis drugs market?

Global Atopic Dermatitis Market Analysis 2019-2024: This Market was Valued at USD 9095.16 Million in 2018 - ResearchAndMarkets.com

Thursday, February 6, 2020 - 1:01pm

5.1 Competitive Scenario of Atopic Dermatitis: By Therapy

Key Points: 
  • 5.1 Competitive Scenario of Atopic Dermatitis: By Therapy
    6.1 Competitive Scenario of Global Atopic Dermatitis: By End User
    7.1 Competitive Scenario of Global Atopic Dermatitis: By Region
    8.1 Americas Atopic Dermatitis Market: Size and Forecast (2019-2024)
    8.3 Market Segmentation By Therapy (Biologic, Oral, Topical, photo)
    8.4 Market Segmentation By End User (Hospitals, Clinics, Research Labs)
    8.5 Americas Atopic Dermatitis Market: Country Analysis
    8.6 Market Opportunity Chart of Americas Atopic Dermatitis Market- By Country, By Value (Year-2024)
    8.8 United States Atopic Dermatitis Market: Size and Forecast (2019-2024)
    8.9 United States Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
    8.10 Canada Atopic Dermatitis Market: Size and Forecast (2019-2024)
    8.11 Canada Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
    8.12 Mexico Atopic Dermatitis Market: Size and Forecast (2019-2024)
    8.13 Mexico Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
    8.14 Brazil Atopic Dermatitis Market: Size and Forecast (2019-2024)
    8.15 Brazil Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
    8.16 Rest of Americas Atopic Dermatitis Market: Size and Forecast (2019-2024)
    8.17 Rest of Americas Atopic Dermatitis Market Segmentation By Therapy, End User (2019-2024)
    10.
  • Asia Pacific Atopic Dermatitis Market: Segmentation By Therapy, End User (2019-2024)
    11.1 ROW Atopic Dermatitis Market: Size and Forecast (2019-2024)
    11.2 ROW Atopic Dermatitis Segmentation By Therapy (Biologic, Oral, Topical, photo)
    11.3 ROW Atopic Dermatitis Segmentation By End User (Hospitals, Clinics, Research Labs)